Cytokinetics logged a 1.8% change during today's afternoon session, and is now trading at a price of $84.77 per share. The S&P 500 index moved -0.0%. CYTK's trading volume is 5,055,835 compared to the stock's average volume of 2,317,540.
Cytokinetics trades 1.81% away from its average analyst target price of $83.26 per share. The 19 analysts following the stock have set target prices ranging from $48.0 to $110.0, and on average have given Cytokinetics a rating of buy.
Anyone interested in buying CYTK should be aware of the facts below:
-
Cytokinetics has moved 81.7% over the last year, and the S&P 500 logged a change of 24.6%
-
Based on its trailing earnings per share of -5.55, Cytokinetics has a trailing 12 month Price to Earnings (P/E) ratio of -15.3 while the S&P 500 average is 15.97
-
CYTK has a forward P/E ratio of -18.8 based on its forward 12 month price to earnings (EPS) of $-4.51 per share
-
The company has a price to earnings growth (PEG) ratio of -1.12 — a number near or below 1 signifying that Cytokinetics is fairly valued compared to its estimated growth potential
-
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases.
-
Based in South San Francisco, the company has 409 full time employees and a market cap of $8.31 Billion.